NVO Novo Nordisk A/S Common Stock
$48.76
Price · Jul 6, 2026
52W Range
$35–$72
37% of range
Analyst Rating
HOLD
37 analysts
Price Target
$47
P/E (TTM)
—
ROE
—
Net Profit Margin
—
NVO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$48.76
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$35 – $72
NVO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
NVO
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
NVO
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
NVO
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
NVO
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
NVO
Peer Median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Dividend Yield
—
Payout Ratio
—
5Y Div CAGR
—
| Ex-date | Amount |
|---|---|
| March 30, 2026 | $1.2750 |
| Aug. 18, 2025 | $0.5840 |
| March 31, 2025 | $1.0990 |
| Aug. 16, 2024 | $0.5130 |
| March 22, 2024 | $0.9300 |
| Aug. 18, 2023 | $0.4420 |
| March 24, 2023 | $0.5945 |
| Aug. 12, 2022 | $0.2920 |
| March 25, 2022 | $0.5180 |
| Aug. 16, 2021 | $0.2785 |
| March 26, 2021 | $0.4745 |
| Aug. 14, 2020 | $0.2590 |
| March 27, 2020 | $0.3935 |
| Aug. 16, 2019 | $0.2245 |
| March 22, 2019 | $0.3945 |
| Aug. 17, 2018 | $0.2335 |
| March 23, 2018 | $0.3350 |
| Aug. 17, 2017 | $0.2370 |
| March 23, 2017 | $0.3315 |
| Aug. 11, 2016 | $0.2235 |
NVO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
HOLD
37 analysts
- Strong Buy 5 13.5%
- Buy 7 18.9%
- Hold 23 62.2%
- Sell 1 2.7%
- Strong Sell 1 2.7%
12-Month Price Target
12 analysts · 2026-07-01
Median
$45.06
Mean
$47.39
Now
$48.76
Low
$39.49
High
$62.89
Median target
$45.06
-7.6%
Mean target
$47.39
-2.8%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.20%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $6.63 | $5.39 | 1.2% |
| Dec. 31, 2025 | $6.04 | $5.96 | 0.08% |
| Sept. 30, 2025 | $4.50 | $4.84 | -0.34% |
| June 30, 2025 | $5.96 | $6.03 | -0.07% |
| March 31, 2025 | $6.04 | $5.96 | 0.08% |
Latest News Recent headlines mentioning this company
- Here's Why Viking Therapeutics Stock Surged Higher in June
- Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
- Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?
- Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
- Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
- Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
- Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
- Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
- 3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
- Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.